Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octagam plus Standard of Care in COVID-19
NCT04411667Phase 4Completed
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of intravenous immunoglobulin G in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Mechanical Ventilation at 45 days. Started Apr 2020; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04411667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411667.